1. Market Research
  2. > Pathology
About 300 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)

  • $ 900
  • June 2020
  • 82 pages

B-cell lymphomas can be categorized into aggressive NHL, such as diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and burkitt' s lymphoma (BL), and indolent NHL, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma

  • Autoimmune Disease
  • Lymphoma
  • Therapy
  • World
  • AbbVie Inc.

Market Spotlight: Hodgkin’s Lymphoma, Pharma Intelligence

  • $ 1318
  • April 2020
  • 40 pages

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, ...

  • Autoimmune Disease
  • Lymphoma
  • Pathology
  • United States
  • World

Global Autoimmune Disease Diagnostic Market (By Disease, Tests Type, Regions), Key Company Profiles - Forecast to 2026

  • $ 1890
  • November 2019
  • 137 pages

lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

  • Autoimmune Disease
  • Diagnostics
  • Lymphoma
  • Pathology
  • World

Wearable Injectors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type ; Application ; End User ; and Geography

  • $ 4550
  • June 2020
  • 184 pages

The wearable injectors market was valued at US$ 5,791.23 million in 2019 and is projected to reach US$ 13,880.88 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020-2027. Wearable injectors ...

  • Autoimmune Disease
  • Diabetes
  • Lymphoma
  • United States
  • Forecast

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • June 2018
  • 272 pages

THEY COULD ALSO BE AT A HIGHER RISK OF DEVELOPING SHINGLES AND AN INCREASE OF LYMPHOMA AND CANCERS.

  • Autoimmune Disease
  • Hospital
  • Lymphoma
  • Medical Biotechnology
  • Therapy

Europe Pharmaceutical Drug Delivery Market Forecast to 2027 - Covid-19 Impact and Regional Analysis By  Route of Administration ; Application ; End User ; and Country

  • $ 3000
  • June 2020
  • 145 pages

Novartis has received the US Food and Drug Administration (FDA) approved for the Zykadia, which is used for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)positive.

  • Autoimmune Disease
  • Lymphoma
  • Pharmaceutical
  • Forecast
  • GlaxoSmithKline plc

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

  • $ 4995
  • September 2018
  • 141 pages

However, Humira is packaged with a boxed warning relating to an increased risk of severe infections, such as tuberculosis and bacterial sepsis, and an increased risk of malignancy, such as lymphomas, for patients taking this drug.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Lymphoma
  • Therapy

The Global Dermatology Market to 2028

  • $ 2849
  • June 2018
  • 180 pages

The global dermatological (prescription) drugs market was valued at $38.4bn in 2017, GMR Data forecast that this will rise to $44.1bn across 2018. The third in a series of biennial Dermatology reports ...

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatology
  • Lymphoma
  • Therapy

Rituxan 2018 U.S. PROMOTIONAL AUDIT REPORT

  • $ 1850
  • July 2019
  • 25 pages

PROMOTIONAL AUDIT REPORT The ## Key Questions Addressed by this Report: • How many physicians were reached by Rituxan through reportable promotional activity in 2018 and how does this compare to its peer set in the Chronic Lymphocytic Leukemia, Follicular Lymphoma, Microscopic Polyangiitis,

  • Autoimmune Disease
  • Health Care Provider
  • Health Services
  • Lymphoma
  • United States

Global Vasculitis Treatment Market 2017-2021

  • $ 2500
  • June 2017
  • 78 pages

TECHNAVIO.

  • Autoimmune Disease
  • Lymphoma
  • Therapy
  • Bristol-Myers Squibb Company
  • Celgene Corporation

Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

  • $ 4995
  • June 2018
  • 125 pages

Many of the most effective agents used to treat severe psoriasis can have harsh adverse effects, and may increase the risk of significant morbidity, including skin cancer, lymphoma and liver disease.

  • Autoimmune Disease
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

  • $ 4995
  • July 2017
  • 136 pages

In addition, the reported lymphoma cases were no greater than the expected rate in the general population (Munzenberger and Montejo, 2007).

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatology
  • Lymphoma
  • Therapy

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • January 2017
  • 345 pages

CANCERS SUCH AS LYMPHOMA ARE ASSOCIATED WITH ANTI-TNF-Α USE AND ARE SEEN more commonly than in the general population (Gordon et al., 2015).

  • Autoimmune Disease
  • Epidemiology
  • Lymphoma
  • Therapy
  • Remicade group

Global Immunology Market 2018-2022

  • $ 2500
  • January 2018
  • 117 pages

lymphoma Product launches DEVELOPMENT M& A AND DIVESTITURES NEW PLANTS, OFFICES, AND LOCATIONS AWARDS AND RECOGNITIONS PRODUCT APPROVALS M& A and divestitures ABBVIE: GEOGRAPHIC FOCUS High Medium Low Americas EMEA APAC ABBVIE: SEGMENT FOCUS Immunology Oncology Neuroscience Virology Ge

  • Autoimmune Disease
  • Immunology
  • Infectious Disease
  • Lymphoma
  • AbbVie Inc.

Global Immunohematology Market 2016-2020

  • $ 2500
  • September 2016
  • 99 pages

In October 2014, it received the breakthrough therapy designation from the US FDA to treat EGFR mutation-negative and anaplastic lymphoma kinase rearrangement-negative NSCLC.

  • Autoimmune Disease
  • Immunotherapy
  • Lymphoma
  • Therapy
  • Vaccine

Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

  • $ 4995
  • June 2017
  • 140 pages

Do RA and lymphoma share risk factors?

  • Autoimmune Disease
  • Immunology
  • Lymphoma
  • Monoclonal Antibody
  • Therapy

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 100 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Autoimmune Disease
  • Biopharmaceutical
  • Lymphoma
  • Pharmaceutical
  • Therapy

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2020

  • $ 3500
  • June 2020
  • 68 pages

Key findings include: CA-## was demonstrated to be generally well-tolerated; patients enrolled to date include patients with tumor types of DLBCL, WM, marginal zone lymphoma, follicular lymphoma, and lymphoplasmacytic lymphoma.

  • Autoimmune Disease
  • Lymphoma
  • Protein Therapy
  • Therapy
  • United States

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H1 2020

  • $ 3500
  • June 2020
  • 104 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Autoimmune Disease
  • Biopharmaceutical
  • Lymphoma
  • Pharmaceutical
  • Therapy

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

  • $ 2500
  • November 2016
  • 98 pages

It has many comorbidities related to it such as diabetes, metabolic disorders, chronic respiratory diseases, lymphomas, hypertension, and other cardiovascular disorders.

  • Autoimmune Disease
  • Cancer Immunotherapy
  • Lymphoma
  • Therapy
  • AbbVie Inc.
View report >

Global Autoimmune Disease and Dermatological Condition Statistics

  • January 2020
  • 34 pages

SELECT JANUS KINASE SIGNALING PATHWAYS *APPROVED JAKINIBS HAVE BOXED WARNINGS FOR SEVERE INFECTION RISK, HEIGHTENED RISK OF LYMPHOMA DEVELOPMENT, AND THROMBOSISIMAGE FROM BRISTOL-MYERS SQUIBB COMPANY EPORTS; ^SOURCE: EVALUAT P ARMA > $##. ## B CONSENSUS SALES FORBMS- (LEAD TYK)^ TYK##: BEST-I

  • Autoimmune Disease
  • Dermatological Condition
  • Immunotherapy
  • Monoclonal Antibody
  • Pathology

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on